The earnings call highlighted Ardelyx's strong financial performance, driven by significant growth in IBSRELA and XPHOZAH revenue. The introduction of a new compound, ARDX-10531, marks a positive step in pipeline development. However, challenges remain, particularly in achieving XPHOZAH's long-term revenue goals amidst market disruptions.

Company Guidance

During the Ardelyx Third Quarter 2025 Earnings Conference Call, the company reported strong financial and operational performance, leading to revised guidance for the year. Notably, IBSRELA generated $78.2 million in revenue, marking a 92% year-over-year increase, and is expected to achieve between $270 million and $275 million in revenue for the year. XPHOZAH also contributed significantly, with $27.4 million in revenue, a 9% increase from the previous quarter. Overall, Ardelyx reported total revenue of $110.3 million, a 12% increase from the same quarter last year. The company highlighted a robust commercial strategy and ongoing investment in pipeline development, including the announcement of ARDX-10531, a next-generation NHE3 inhibitor. Ardelyx aims for sustainable growth, leveraging its strong cash position and strategic initiatives to drive long-term shareholder value.

Record Product Revenue

Ardelyx generated $105.5 million in product revenue during the third quarter, representing a 15% year-over-year growth.

IBSRELA's Strong Performance

IBSRELA generated $78.2 million during the third quarter, marking a 92% increase over last year. The company raised its guidance and expects to generate between $270 million and $275 million in IBSRELA revenue this year.

XPHOZAH Revenue Growth

XPHOZAH generated $27.4 million in revenue, a 9% increase compared to Q2. The team remains focused on ensuring patient access and strengthening clinical conviction among nephrologists.

Introduction of ARDX-10531

Ardelyx announced ARDX-10531, a next-generation NHE3 inhibitor, marking an important milestone as the company reinvigorates its pipeline. Preclinical data shows it is a highly potent, highly soluble molecule.

Financial Strength and Guidance Increase

The company ended the quarter with $242.7 million of cash, cash equivalents, and short-term investments. Ardelyx raised its guidance for IBSRELA revenue for the year.

Ardelyx (ARDX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ARDX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 11, 2026	2025 (Q4)	<0.01 / -	0.02	―	―	―
Oct 30, 2025	2025 (Q3)	-0.06 / 0.00	0	―	―
Aug 04, 2025	2025 (Q2)	-0.13 / -0.08	-0.07	-14.29% (>-0.01)	―
May 01, 2025	2025 (Q1)	-0.11 / -0.17	-0.11	-54.55% (-0.06)	―
Feb 20, 2025	2024 (Q4)	<0.01 / 0.02	-0.12	116.67% (+0.14)	―
Oct 31, 2024	2024 (Q3)	-0.05 / 0.00	0.03	―	―
Aug 01, 2024	2024 (Q2)	-0.11 / -0.07	-0.08	12.50% (<+0.01)	―
May 02, 2024	2024 (Q1)	-0.15 / -0.11	-0.13	15.38% (+0.02)	―
Feb 22, 2024	2023 (Q4)	-0.10 / -0.12	0.06	-300.00% (-0.18)	―
Oct 31, 2023	2023 (Q3)	-0.11 / 0.03	-0.14	121.43% (+0.17)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ARDX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 30, 2025	$5.01	$6.06	+20.96%
Aug 04, 2025	$4.39	$5.13	+16.86%
May 01, 2025	$5.47	$4.13	-24.50%
Feb 20, 2025	$6.36	$5.72	-10.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.